Research Disclosures & Disclaimers

This website contains disclosures and disclaimers related to
published UBS Global Research products, including those related to
regulation, potential conflicts of interest as well as those provided
by third-party data providers describing limitations on use of their
products.

Haleon (HLN.L)*

UBS Rating and Price Target History Chart

Line chart explaining Price target vs Stock Price is described in below table

EQ Rating & Price Target Table

Date Stock Price (p) Price Target (p) Rating
2022-03-30NaN-No Rating
2022-07-19301380Buy
2022-10-14274410Buy
2023-01-13325400Buy
2023-04-21352410Buy
2023-10-10340430Buy
2023-11-02320420Buy
2024-01-15334410Buy
2024-10-07377445Buy
2025-01-10372450Buy
2025-04-07357443Buy
2025-05-02398460Buy

Disclosures

  • UBS has acted as manager/co-manager in the underwriting or placement of securities of this company/entity or one of its affiliates within the past 12 months.
  • UBS is acting as buy-side financial adviser to Haleon PLC on its acquisition of the remaining 12% equity interest in Tianjin TSKF Pharmaceutical Co., Ltd.
  • Within the past 12 months, UBS has received compensation for investment banking services from this company/entity or one of its affiliates.
  • UBS AG London Branch acts as broker to this company.
  • UBS Securities LLC makes a market in the securities and/or ADRs of this company.
  • UBS holds a long or short position of 0.5% or more of the listed shares of this company.
Note : Historical Price Targets have been adjusted to account for any stock splits, rights issues and/or dividends which may have occurred for this security. Not Priced: Stock was not priced on the given date. No Rating: Issuer was not rated by UBS on the given day. No Price Target: For this issuer no Price Target was set by UBS on the given day. Issuers with an EQ Rating & Price Target Table are covered by UBS-IB Equity Research Analysts. Issuers without an EQ Rating & Price Target Table are not single stock covered.

* Issuers marked with an asterisk are covered by UBS-IB Equity Research Analysts. Issuers without an asterisk are not single stock covered.